XTL Biopharmaceuticals Statistics
Share Statistics
XTL Biopharmaceuticals has 8.81M
shares outstanding. The number of shares has increased by 191.25%
in one year.
| Shares Outstanding | 8.81M |
| Shares Change (YoY) | 191.25% |
| Shares Change (QoQ) | 15.9% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 2.48% |
Short Selling Information
The latest short interest is 38.38K, so 0.44% of the outstanding
shares have been sold short.
| Short Interest | 38.38K |
| Short % of Shares Out | 0.44% |
| Short % of Float | 0.57% |
| Short Ratio (days to cover) | 2.5 |
Valuation Ratios
The PE ratio is -13.3 and the forward
PE ratio is null.
XTL Biopharmaceuticals's PEG ratio is
0.
| PE Ratio | -13.3 |
| Forward PE | n/a |
| PS Ratio | 30.29 |
| Forward PS | n/a |
| PB Ratio | 2.51 |
| P/FCF Ratio | -8.17 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for XTL Biopharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.61 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.08 |
| Interest Coverage | -77.57 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $45,100 |
| Profits Per Employee | $-102,700 |
| Employee Count | 10 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -130K |
| Effective Tax Rate | 11.24% |
Stock Price Statistics
The stock price has increased by -57.94% in the
last 52 weeks. The beta is 0.99, so XTL Biopharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | -57.94% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 40.28 |
| Average Volume (20 Days) | 8,065 |
Income Statement
In the last 12 months, XTL Biopharmaceuticals had revenue of 451K
and earned -1.03M
in profits. Earnings per share was -0.15.
| Revenue | 451K |
| Gross Profit | 3K |
| Operating Income | -2.17M |
| Net Income | -1.03M |
| EBITDA | -930K |
| EBIT | -1.13M |
| Earnings Per Share (EPS) | -0.15 |
Full Income StatementBalance Sheet
The company has 371K in cash and 138K in
debt, giving a net cash position of 233K.
| Cash & Cash Equivalents | 371K |
| Total Debt | 138K |
| Net Cash | 233K |
| Retained Earnings | -159.01M |
| Total Assets | 8.55M |
| Working Capital | -867K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -1.62M
and capital expenditures -54K, giving a free cash flow of -1.67M.
| Operating Cash Flow | -1.62M |
| Capital Expenditures | -54K |
| Free Cash Flow | -1.67M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
Gross margin is 0.67%, with operating and profit margins of -481.6% and -227.72%.
| Gross Margin | 0.67% |
| Operating Margin | -481.6% |
| Pretax Margin | -256.54% |
| Profit Margin | -227.72% |
| EBITDA Margin | -206.21% |
| EBIT Margin | -481.6% |
| FCF Margin | -370.73% |
